Pandorum Technologies Secures $18M Series B to Advance Exosome-Based Regenerative Therapies
核心洞察
Pandorum Technologies (搜索) raised $18 million in Series B funding led by Protons Corporate (搜索) to advance clinical development of its programmable exosome-based regenerative therapies.
The company's lead therapy Kuragenx (搜索) has received FDA Orphan Drug Designation for treating rare ocular surface diseases including Stevens-Johnson Syndrome (搜索) and Neurotrophic Keratitis (搜索).
Funding will support global manufacturing scale-up through partnerships with AGC Biologics and Nucelion Therapeutics (搜索), while expanding operations across the US, Japan, and Middle East markets.
Pandorum Technologies (搜索), a Bengaluru-based biotechnology company pioneering programmable regenerative medicine, has closed an $18 million Series B financing round to advance clinical development of its disease-modifying, tunable, exosome-based therapies. The funding will support scaling global manufacturing and expanding operations across the United States, Japan, and the Middle East.
The round was led by Protons Corporate (搜索), with participation from Galentic Pharma (搜索), marquee investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family and others. Bandana Kankani, advisor and investor at Pandorum, guided the transaction, optimizing the alignment between the investment architecture and company's value creation.
Proprietary Platform Technology
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum's proprietary platform combines biology, engineering, and computation to develop tunable, regenerative exosome therapies that reprogram pathological tissue states, like inflammation and fibrosis, toward functional recovery. The company operates in both India and the United States, reflecting its focus on global clinical translation and manufacturing.
Global Manufacturing Strategy
Pandorum has implemented a globally distributed manufacturing strategy to support its clinical programs. The company has partnered with AGC Biologics in Italy for the US and European markets, and established a strategic collaboration with Nucelion Therapeutics (搜索), a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. The company is also exploring potential partnerships in the Middle East to strengthen regional access and distribution.
Clinical Focus on Rare Ocular Diseases
Pandorum's primary focus is on ocular surface diseases, such as Stevens-Johnson Syndrome (搜索) and Neurotrophic Keratitis (搜索). The company's lead ophthalmology program, Kuragenx (搜索), has received US FDA Orphan Drug Designation for these rare conditions. Beyond ophthalmology, Pandorum is expanding its tunable platform to address systemic conditions, including inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.
Clinical Translation Network
The company's clinical translation efforts are supported by a network of internationally recognized clinicians, including Dr. Virender Singh Sangwan of Dr. Shroff's Charity Eye Hospital in New Delhi, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine in Chicago.
Funding Allocation and Growth
According to startup data platform TheKredible, Pandorum has raised approximately $43 million to date, including an $11 million extension of its Series A funding secured last year. The fresh capital will be used to advance Pandorum's clinical-stage programs, scale up manufacturing operations, and expand market access. Part of the funding will also be allocated to strengthening regulatory capabilities and clinical development infrastructure as the company prepares for broader global trials.